By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Chemin des Aulx, 12
1228 Plan-les-Ouates
  Geneva    Switzerland
Phone: n/a Fax: n/a


Company News
ObsEva Release: Company Expands Leadership Team And Board Of Directors With Industry Veterans 1/17/2017 7:15:38 AM
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017 7:39:17 AM
ObsEva Announces Plans To Conduct Initial Public Offering In The United States 10/17/2016 7:09:48 AM
ObsEva To Webcast Presentation At 15th Annual Needham Healthcare Conference 4/5/2016 10:51:10 AM
ObsEva Strengthens Board With Appointment Of Biotechnology Veteran Dr. Frank Verwiel 3/24/2016 7:44:28 AM
ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis 11/20/2015 7:57:26 AM
ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study 6/23/2015 6:24:40 AM
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015 7:22:26 AM
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014 11:49:49 AM
ObsEva Lands $34.5 Million Series A Funding, License Agreement With Merck Serono 8/29/2013 6:56:52 AM